Mr. Tyler Dunn reports

ZENTEK FILES A PROVISIONAL PATENT ON THE USE OF ZENGUARD(TM) AS AN ANTI-INFLAMMATORY AGENT

Zentek Ltd. has filed a provisional patent on the use of ZenGuard as an anti-inflammatory agent for dermatological conditions.

"We continue to work diligently to secure patents for our various intellectual property," said Greg Fenton, chief executive officer for Zentek. "This is another demonstration of how we are further commercializing our unique ZenGuard technology, which is already well researched, developed and authorized by Health Canada for use as an antimicrobial agent on surgical masks and other PPE [personal protective equipment]."

ZenGuard, as a dermatological product, is currently being researched for treatment of various skin conditions, including both infectious and inflammatory conditions like acne, psoriasis, eczema, sunburn, poison ivy, warts, seborrheic dermatitis and toenail fungal infections. As reported on March 10, 2022, Zentek is conducting preclinical research with Vimta Labs to collect data that are required for the submission of an investigational new drug to the United States Food and Drug Administration (FDA), a requirement for the administration of new drugs in humans.

About Zentek Ltd.

Zentek is an IP (intellectual property) development and commercialization company focused on next-generation health care solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGuard, a patent-pending coating shown to have over 99-per-cent antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.

We seek Safe Harbor.